About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Liver Diseases group is a referent at the local, national and international level in research, and is one of the most active groups in clinical research at VHIR. The group's prominent involvement in clinical trials is a clear indication of our professionals' commitment to ensuring that patients have access to state-of-the-art therapies. Our participation and collaboration in international projects and consortiums are also a fundamental characteristic of the group. The main objective of the group is to become one of the best translational research groups in liver diseases. It is essential to be able to apply all the findings of basic research to clinical research to improve the health of patients with liver disease.
IP: NANOPARTICULAS BIODEGRADABLES DE SIMVASTATINA COMO NUEVA HERRAMIENTA TERAPÉUTICA PARA LA ENFERMEDAD HEPÁTICA CRÓNICA Collaborators: Immaculada Raurell Saborit, Ester Palacio Gutierrez Funding agency: Instituto de Salud Carlos III Funding: 75020 Reference: PI17/00754 Duration: 01/01/2018 - 31/12/2020
IP: - Collaborators: David Tabernero Caellas Funding agency: Gilead Sciences, S.L.U. Funding: 48599.7 Reference: GLD17/00276 Duration: 16/01/2018 - 15/01/2020
IP: Beatriz Minguez Rosique Collaborators: Itxarone Izaskun Bilbao Aguirre, Maria Teresa Salcedo Allende, Monica Higuera Urbano Funding agency: Instituto de Salud Carlos III Funding: 129470 Reference: PI18/00961 Duration: 01/01/2019 - 31/12/2022
IP: - Collaborators: Lluis Castells Fusté, Andrea Caballero Garralda, David Tabernero Caellas, Maria Francesca Cortese Funding agency: Instituto de Salud Carlos III Funding: 159720 Reference: PI18/01436 Duration: 01/01/2019 - 31/12/2022
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
This tool will help avoid invasive techniques and assist in selecting candidates for clinical trials of new treatments.
Des de Vall d'Hebron estem buscant 200 persones voluntàries sanes d'entre 18 i 30 anys per a participar en un estudi sobre els patrons de consum habitual de l'alcohol en població jove, en el marc del projecte StopALD.
